ARVN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ARVN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Arvinas's yield on cost for the quarter that ended in Mar. 2024 was 0.00.
The historical rank and industry rank for Arvinas's 5-Year Yield-on-Cost % or its related term are showing as below:
For the Biotechnology subindustry, Arvinas's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Arvinas's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Arvinas's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Arvinas is calculated as
Yield-on-Cost | = | Dividend Yield % | * | (1 | + | Dividend Growth Rate)^5 |
Arvinas (NAS:ARVN) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Thank you for viewing the detailed overview of Arvinas's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.
Ronald Peck | officer: Chief Medical Officer | C/O ARVINAS, INC., 5 SCIENCE PARK, 395 WINCHESTER AVE., NEW HAVEN CT 06511 |
Sunil Agarwal | director | 60 LEVERONI COURT, NOVATO CA 94949 |
Ian Taylor | officer: Senior Vice President, Biology | C/O ARVINAS, INC., 5 SCIENCE PARK, 395 WINCHESTER AVENUE, NEW HAVEN CT 0651 |
John G Houston | director, officer: President and CEO | C/O ARVINAS, INC., 5 SCIENCE PARK, 395 WINCHESTER AVE., NEW HAVEN CT 06511 |
Sean A Cassidy | officer: Chief Financial Officer | 322 EAST MAIN STREET, BRANFORD CT 06405 |
Everett Cunningham | director | C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094 |
David K Loomis | officer: Chief Accounting Officer | C/O 5 SCIENCE PARK, 385 WINCHESTER AVENUE, NEW HAVEN CT 06511 |
John D Young | director | C/O CORPORATE SECRETARY, 235 EAST 42ND ST., NEW YORK NY 10017 |
Briggs Morrison | director | C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD, SUITE 110, WALTHAM MA 02451 |
Liam Ratcliffe | director, 10 percent owner | C/O ACCESS INDUSTRIES, INC, 40 WEST 57TH ST, 28TH FLOOR, NEW YORK NY 10019 |
Timothy M Shannon | director | C/O CURAGEN CORP, 555LONG WHARF DR. 11TH FL., NEW HAVEN CT 06511 |
Bradley Albert Margus | director | C/O ARVINAS, INC., 5 SCIENCE PARK, 395 WINCHESTER AVE., NEW HAVEN CT 06511 |
Kennedy Edward Moore Jr. | director | C/O ARVINAS, INC. 5 SCIENCE PARK, 395 WINCHESTER AVENUE, NEW HAVEN CT 06511 |
Wendy L Dixon | director | |
Linda Bain | director | C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
From GuruFocus
By sperokesalga sperokesalga • 06-08-2023
By GlobeNewswire • 10-22-2023
By Marketwired • 10-15-2023
By sperokesalga sperokesalga • 02-27-2023
By PurpleRose PurpleRose • 08-18-2022
By Value_Insider Value_Insider • 10-27-2022
By Value_Insider Value_Insider • 11-01-2022
By sperokesalga sperokesalga • 04-21-2023
By GlobeNewswire • 01-16-2024
By Ds*** Ds*** • 08-31-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.